What dose of Femara (letrozole) do men use?

Strength and label dose
SourceStrength and schedulePeople
US labelOne 2.5 mg tablet once a day1Postmenopausal women with breast cancer
US label, liver disease2.5 mg every other day1Patients with cirrhosis and severe hepatic dysfunction
UK SmPC2.5 mg once daily3Adult and elderly patients, with no adjustment for elderly patients; indicated for postmenopausal women with breast cancer

The Femara label gives one 2.5 mg tablet once a day for postmenopausal women with breast cancer and lists no use in men; in a 2026 trial by Sun and colleagues, 296 men with spermatogenic failure were given, for 3 months, letrozole 2.5 mg daily with vitamins C and E, against the vitamins alone.12

Strength and label dose

The table is set at the top of the page

Femara is supplied as 2.5 mg tablets, in bottles of 30 on the US label.1 The US label says the tablets are taken orally without regard to meals.1 Its indication is postmenopausal women with breast cancer, and no use in men is listed.1

What trials in men used

TrialDose and schedulePeopleLength
Sun et al. (2026)Letrozole 2.5 mg once daily plus vitamin C 100 mg and vitamin E 100 mg, against the vitamins alone2296 men with spermatogenic failure: 147 on letrozole, 149 on control3 months
Trunet et al. (1993)Single doses from 0.02 to 30 mg across nine dose levels, and placebo, 3 men each418 healthy menSingle dose

In 750 infertile women with polycystic ovary syndrome, Legro et al. gave letrozole 2.5 mg daily against clomiphene 50 mg daily, from cycle day 3 for 5 days, for up to five menstrual cycles, with a maximum letrozole dose of 7.5 mg (three pills) a day for 5 days.5 The sources do not define a letrozole "cycle" in men; the only cycle in a trial is the menstrual cycle.

TRT, cycles and what is not known

The Society for Endocrinology says evidence for aromatase inhibitors after non-medical androgen use is limited and of low quality.6 It says many men who stop or cycle in and out of such use self-administer so-called post-cycle therapy, typically hCG, SERMs or aromatase inhibitors.6 It says Rasmussen et al. randomised symptomatic men with a history of non-medical androgen use and low testosterone to letrozole or placebo, and that the study was terminated early because of poor recruitment; the statement gives no number of men.6 A ClinicalTrials.gov entry for the LUCAS trial (NCT05205837) planned 24 weeks of letrozole starting at 2.5 mg each day against placebo in men with hypogonadism after anabolic steroid use, with hCG 1500 IE twice weekly added after four weeks if testosterone had not reached its target; it was terminated for lack of recruitment, with an actual enrolment of 8.7 In Loves et al. (2013), a 6-month placebo-controlled trial in 42 obese men with a BMI over 35 kg/m2 and total testosterone under 10 nmol/l, letrozole started at one 2.5 mg tablet a week, with dose escalation every month until total testosterone reached 20 nmol/l.8 A ClinicalTrials.gov registry entry, NCT07922512, with no results posted, describes 60 men with oligospermia and a low testosterone to estradiol ratio, given letrozole 2.5 mg once daily for 3 months, against placebo.9 The sources report no human trial of letrozole with testosterone replacement or with clomiphene in men. No Femara or letrozole figure from Milligram's logs is shown.

Storage, mixing and syringes

The US label gives storage at 20°C to 25°C, with excursions permitted between 15°C and 30°C.1 The UK SmPC gives a 3-year shelf life, a 30°C ceiling, and storage in the original package against moisture.3

Neither label describes a liquid, powder or injectable Femara, or an instruction to dissolve, crush or split the tablet. With no concentration in mg per mL, no syringe mark applies.

Frequently asked questions

Is letrozole prohibited in sport for men?

The WADA Prohibited List puts hormone and metabolic modulators (class S4) in the group prohibited in and out of competition.10 The 2026 list names letrozole among the aromatase inhibitors (S4.1).10

What does the Femara label say about safety?

The US label lists pregnancy as a contraindication because letrozole can cause fetal harm.1 In a label trial in women given letrozole or tamoxifen, median lumbar spine bone density fell 4.1% on letrozole and rose 0.3% on tamoxifen at 24 months.1 In the 2026 trial in 296 men with spermatogenic failure, decreased libido was reported in 12.2% of men on letrozole and 5.4% on vitamins alone.2

References

  1. Novartis (DailyMed). These highlights do not include all the information needed to use FEMARA safely and effectively. See full prescribing information for FEMARA. FEMARA (letrozole) tablets, for oral use Initial U.S. Approval: 1997. 2026. dailymed.nlm.nih.gov
  2. PMC. Letrozole and Infertility Among Males With Spermatogenic Failure. 2026. pmc.ncbi.nlm.nih.gov
  3. Novartis (emc). Femara 2.5 mg Tablets - Summary of Product Characteristics (SmPC) - (emc) | 1029. medicines.org.uk
  4. PubMed. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. 1993. pubmed.ncbi.nlm.nih.gov
  5. PMC. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome. 2014. pmc.ncbi.nlm.nih.gov
  6. Society for Endocrinology. Management of non-medical androgen use: a position statement by the Society for Endocrinology. 2026. pmc.ncbi.nlm.nih.gov
  7. ClinicalTrials.gov. NCT05205837: A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial. 2023. clinicaltrials.gov
  8. PubMed. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia. 2013. pubmed.ncbi.nlm.nih.gov
  9. ClinicalTrials.gov. NCT07922512: Letrozole in Oligospermia With Eugonadotropic-Hypogonadism and Low Testosterone Estradiol Ratio. 2024. clinicaltrials.gov
  10. WADA. WORLD ANTI-DOPING CODE. wada-ama.org